Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease

Summary

Multicenter, prospective, non-controlled study in a pediatric cohort (\<6 years-old) with severe (type 2 or 3) hereditary Von Willebrand Disease (VWD).

Timeline

Start

2013-12

Primary completion

2024-12-10

Completion

2024-12-10

Outcome

Outcome not reported

Stopped (Enrollment): “Due to recruitment difficulties for pediatric patients. The reason for study cancellation is not related to safety concerns or any adverse events.”

Drugs

Indications